Redefining tomorrow, today.
Covers 740+ genes
and is the first to
unlock epigenomics2,3*
EUAA
High sensitivity
with a reportable range
down to 0.001% MAF2
MAF, mutant allele fraction.
*Guardant360 Liquid is the first and only commercially available liquid biopsy to unlock genomics and epigenomics from a single input.
Home Oncology Portfolio Partnerships European Policy
Guardant360 Liquid is developed as Laboratory Developed Tests (LDTs) and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Product availability may vary depending on country/region. Guardant360 Liquid is not approved nor marketed in EU.
Fast results
in 7 days2†